Actively Recruiting
Study of All-trans Retinoic Acid Combined With KPD Regimen for Treating Relapsed or Refractory Multiple Myeloma in Adults
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-02-19
25
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of combining All-trans Retinoic Acid ATRA with a KPD regimen in patients who have refractory or relapsed multiple myeloma. This open-label Phase 2 clinical trial aims to measure response rates, survival times, and side effects associated with this treatment combination. The treatment involves a 28-day course where patients receive ATRA orally twice daily for three days, starting two days before carfilzomib administration. The KPD regimen includes carfilzomib given twice weekly for three weeks, pomalidomide taken orally daily for 21 days, and dexamethasone administered orally on specific days each cycle with doses adjusted by age. Treatment continues until disease progression or unacceptable toxicity. Participants will undergo regular assessments for overall response rate, complete response, progression-free survival, and overall survival for up to 26 months. Evaluations include clinical exams, laboratory tests, and monitoring for adverse effects. The study ensures ongoing safety monitoring and follows participants throughout the treatment and observation periods to gather comprehensive data on treatment impact and tolerability.
CONDITIONS
Brief Title
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
Research Team
Z
Zhijuan Lin, PhD
B
Bing Xu, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
